A61K 51/0461
Having six-membered rings with three nitrogens as the only ring hetero atoms
Official title: {having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K51/0472)}
A61K51/0461 (Having six-membered rings with three nitrogens as the only ring hetero atoms) appears on 12 US grants and 21 published applications in this corpus.
Search patents in A61K- Granted patents
- 12
- Published applications
- 21
- Assignees
- 23
- Inventors
- 71
- Latest grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 2 |
| 2004 | 1 | 0 |
| 2005 | 2 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 2 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 2 |
| 2017 | 0 | 0 |
| 2018 | 2 | 2 |
| 2019 | 1 | 0 |
| 2020 | 1 | 2 |
| 2021 | 1 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 2 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy14 Apr 2026US 12,600,742 B2WWIKY Biosciences Inc.
- Organ protection in PSMA-targeted radionuclide therapy of prostate cancer9 Nov 2021US 11,167,049 B2Molecular Insight Pharmaceuticals, Inc.
- Organ protection in PSMA-targeted radionuclide therapy of prostate cancer2 Jun 2020US 10,668,174 B2Molecular Insight Pharmaceuticals, Inc.
- Small molecule imaging of fungi by positron emission tomography scanning20 Aug 2019US 10,383,960 B2The Research Foundation of State Univeristy of New York
- Small molecule imaging of fungi by positron emission tomography scanning15 May 2018US 9,968,693 B2The Research Foundation of State University of New York
- Alpha-synuclein binders and methods of use6 Aug 2026US 2026/0224758 A1Merck Sharp & Dohme Corp.
- Methods of diagnosing and treating neurodegenerative diseases29 May 2025US 2025/0170124 A1The General Hospital Corporation
- Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof4 Jul 2024US 2024/0216557 A1Memorial Hospital for Cancer and Allied Diseases
- Proinflammatory prodrugs21 Dec 2023US 2023/0405129 A1The Boad of Regents of the University of Taxas System
- Compounds and methods for the diagnosis, imaging and treatment of neurodegenerative diseases and disorders2 Mar 2023US 2023/0065420 A1The University of Melbourne
Most cited
By later US patents
- Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors10US 6,911,444 B2Janssen Pharmaceutics, N.V. · 2005
- Organ protection in PSMA-targeted radionuclide therapy of prostate cancer8US 9,956,305 B2Molecular Insight Pharmaceuticals, Inc. · 2018
- Small molecule imaging of fungi by positron emission tomography scanning2US 10,383,960 B2The Research Foundation of State Univeristy of New York · 2019
- Fluoride carrier for positron emission tomography1US 7,723,322 B2The Regents of the University of California · 2010
- Radiolabeled compounds and uses thereof1US 8,168,786 B2The Trustees of Columbia University in the City of New York · 2012